On May 13, 2026, Outlook Therapeutics, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share ("Common Stock"), from time to time through H.C. Wainwright as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the "Shares").

 

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001649989/000110465926060305/tm2614480d1_8k.htm